nach oben

Erschienen in:

11.08.2017 | Original paper

A situational analysis of breast cancer early detection services in Trinidad and Tobago

verfasst von: Kimberly Badal, Fidel Rampersad, Wayne A. Warner, Adetunji T. Toriola, Hamish Mohammed, Harold-Alexis Scheffel, Rehanna Ali, Murrie Moosoodeen, Siva Konduru, Adaila Russel, Rajini Haraksingh

Erschienen in: Cancer Causes & Control | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A situational analysis of breast cancer (BC) early detection services was carried out to investigate whether Trinidad and Tobago (T&T) has the framework for successful organized national screening.

Methods

An online survey was designed to assess the availability, accessibility, quality control and assurance (QC&A), and monitoring and evaluation (M&E) mechanisms for public and private BC early detection. A focus group with local radiologists (n = 3) was held to identify unaddressed challenges and make recommendations for improvement.

Results

Major public hospitals offer free detection services with wait times of 1–6 months for an appointment. Private institutions offer mammograms for TTD$240 (USD$37) at minimum with same day service. Both sectors report a lack of trained staff. Using 1.2 mammograms per 10,000 women ≥40 years as sufficient, the public sector’s rate of 0.19 mammograms per 10,000 women ≥40 years for screening and diagnosis is inadequate. Program M&E mechanisms, QC&A guidelines for machinery use, delays in receipt of pathology reports, and unreliable drug access are further unaddressed challenges.

Conclusion

T&T must first strengthen its human and physical resources, implement M&E and QC&A measures, strengthen cancer care, and address other impediments to BC early detection before investing in nationally organized BC screening.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262 CrossRefPubMed

DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A (2015) International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 24(10):1495–1506. doi:10.1158/1055-9965.EPI-15-0535 CrossRef

Institute NC SEER cancer statistics factsheets: female breast cancer. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 9 Dec 2016

Hashemi SH, Karimi S, Mahboobi H (2014) Lifestyle changes for prevention of breast cancer. Electron Physician 6(3):894–905. doi:10.14661/2014.894-905 PubMedPubMedCentral

Colditz G, Bohlke K (2014) Priorities for the primary prevention of breast cancer. CA 00:1–9. doi:10.3322/caac.21225

Ga Colditz, Bohlke K (2015) Preventing breast cancer now by acting on what we already know. npj. Breast Cancer 19:19–22. doi:10.1038/npjbcancer.2015.9

Hajian S, Vakilian K, Najabadi KM, Hosseini J, Mirzaei HR (2011) Effects of education based on the health belief model on screening behavior in high risk women for breast cancer, Tehran, Iran. Asian Pac J Cancer Prev 12(1):49–54PubMed

Ceber E, Turk M, Ciceklioglu M (2010) The effects of an educational program on knowledge of breast cancer, early detection practices and health beliefs of nurses and midwives. J Clin Nurs 19(15–16):2363–2371. doi:10.1111/j.1365-2702.2009.03150.x CrossRefPubMed

10.

Schopper D, de Wolf C (2009) How effective are breast cancer screening programmes by mammography? Review of the current evidence. Eur J Cancer 45(11):1916–1923. doi:10.1016/j.ejca.2009.03.022 CrossRefPubMed

11.

Burton R, Bell R (2013) The global challenge of reducing breast cancer mortality. Oncologist 18(11):1200–1202. doi:10.1634/theoncologist.2013-0315 CrossRefPubMedPubMedCentral

12.

Jatoi I, Miller AB (2003) Why is breast-cancer mortality declining? Lancet Oncol 4(4):251–254CrossRefPubMed

13.

Luciani S, Cabanes A, Prieto-Lara E, Gawryszewski V (2013) Cervical and female breast cancers in the Americas: current situation and opportunities for action. Bull World Health Organ 91(9):640–649. doi:10.2471/BLT.12.116699 CrossRefPubMedPubMedCentral

14.

Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldana K, Ferreyra M, Debiasi M, Liedke PE, Touya D, Werutsky G, Higgins M, Fan L, Vasconcelos C, Cazap E, Vallejos C, Mohar A, Knaul F, Arreola H, Batura R, Luciani S, Sullivan R, Finkelstein D, Simon S, Barrios C, Kightlinger R, Gelrud A, Bychkovsky V, Lopes G, Stefani S, Blaya M, Souza FH, Santos FS, Kaemmerer A, de Azambuja E, Zorilla AF, Murillo R, Jeronimo J, Tsu V, Carvalho A, Gil CF, Sternberg C, Duenas-Gonzalez A, Sgroi D, Cuello M, Fresco R, Reis RM, Masera G, Gabus R, Ribeiro R, Knust R, Ismael G, Rosenblatt E, Roth B, Villa L, Solares AL, Leon MX, Torres-Vigil I, Covarrubias-Gomez A, Hernandez A, Bertolino M, Schwartsmann G, Santillana S, Esteva F, Fein L, Mano M, Gomez H, Hurlbert M, Durstine A, Azenha G (2013) Planning cancer control in Latin America and the Caribbean. Lancet Oncol 14(5):391–436. doi:10.1016/S1470-2045(13)70048-2 CrossRefPubMed

15.

WHO (2012) Trinidad and Tobago Cancer Profile 2014.2010–2012

16.

Wa Warner, Morrison RL, Lee TY, Williams TM, Ramnarine S, Roach V, Slovacek S, Maharaj R, Bascombe N, Bondy ML, Ellis MJ, Toriola AT, Roach A, AaM Llanos (2015) Associations among ancestry, geography and breast cancer incidence, mortality, and survival in Trinidad and Tobago. Cancer Med. doi:10.1002/cam4.503

17.

Mungrue K, Ramdath J, Ali S, Cuffie WA, Dodough N, Gangar M, Mohammed L, Mungroo V, Ramsahai J, Shah M (2014) Challenges to the control of breast cancer in a small developing country. Breast Cancer 8:7–13. doi:10.4137/BCBCr.s12780 PubMedPubMedCentral

18.

Naraynsingh V, Hariharan S, Dan D, Bhola S, Bhola S, Nagee K (2010) Trends in breast cancer mortality in Trinidad and Tobago-A 35-year study. Cancer Epidemiol. doi:10.1016/j.canep.2009.11.003 PubMed

19.

Taioli E, Attong-Rogers A, Layne P, Roach V, Ragin C (2010) Breast cancer survival in women of African descent living in the US and in the Caribbean: effect of place of birth. Breast Cancer Res Treat 122:515–520. doi:10.1007/s10549-009-0702-9 CrossRefPubMed

20.

Camacho-Rivera M, Ragin C, Roach V, Kalwar T, Taioli E (2015) Breast cancer clinical characteristics and outcomes in Trinidad and Tobago. J Immigr Minor Health 17(3):765–772. doi:10.1007/s10903-013-9930-5 CrossRefPubMed

21.

Murillo R, Diaz S, Perry F, Poveda C, Pineros M, Sanchez O, Buitrago L, Gamboa O, Lozano T, Yu H, Wang CY, Duggan C, Thomas DB, Anderson BO (2016) Increased breast cancer screening and downstaging in Colombian women: a randomized trial of opportunistic breast-screening. Int J Cancer 138(3):705–713. doi:10.1002/ijc.29801 CrossRefPubMed

22.

Lui CY, Lam HS, Chan LK, Tam KF, Chan CM, Leung TY, Mak KL (2007) Opportunistic breast cancer screening in Hong Kong; a revisit of the Kwong Wah Hospital experience. Hong Kong Med J 13(2):106–113PubMed

23.

Teh YC, Tan GH, Taib NA, Rahmat K, Westerhout CJ, Fadzli F, See MH, Jamaris S, Yip CH (2015) Opportunistic mammography screening provides effective detection rates in a limited resource healthcare system. BMC Cancer 15:405. doi:10.1186/s12885-015-1419-2 CrossRefPubMedPubMedCentral

24.

Hertl K, Primic-Zakelj M, Zgajnar J, Kocijancic I (2006) Performance of opportunistic breast cancer screening in Slovenia. Neoplasma 53(3):237–241PubMed

25.

de Gelder R, Bulliard JL, de Wolf C, Fracheboud J, Draisma G, Schopper D, de Koning HJ (2009) Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer 45(1):127–138. doi:10.1016/j.ejca.2008.09.015 CrossRefPubMed

26.

Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375(15):1438–1447. doi:10.1056/NEJMoa1600249 CrossRefPubMed

27.

Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E, Group EW (2012) Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 19(Suppl 1):42–56. doi:10.1258/jms.2012.012082 CrossRefPubMed

28.

Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, Wang Q, Lindfors K, Pisano ED (2014) Consequences of false-positive screening mammograms. JAMA Intern Med 174(6):954–961. doi:10.1001/jamainternmed.2014.981 CrossRefPubMedPubMedCentral

29.

Hofvind S, Ponti A, Patnick J, Ascunce N, Njor S, Broeders M, Giordano L, Frigerio A, Tornberg S, Project E, Euroscreen Working G, Van Hal G, Martens P, Majek O, Danes J, von Euler-Chelpin M, Aasmaa A, Anttila A, Becker N, Pentek Z, Budai A, Madai S, Fitzpatrick P, Mooney T, Zappa M, Ventura L, Scharpantgen A, Hofvind S, Seroczynski P, Morais A, Rodrigues V, Bento MJ, Gomes de Carvalho J, Natal C, Prieto M, Sanchez-Contador Escudero C, Zubizarreta Alberti R, Fernandez Llanes SB, Ascunce N, Ederra Sanza M, Sarriugarte Irigoien G, Salas Trejo D, Ibanez Cabanell J, Wiege M, Ohlsson G, Tornberg S, Korzeniewska M, de Wolf C, Fracheboud J, Patnick J, Lancucki L, Ducarroz S, Suonio E (2012) False-positive results in mammographic screening for breast cancer in Europe: a literature review and survey of service screening programmes. J Med Screen 19(Suppl 1):57–66. doi:10.1258/jms.2012.012083 CrossRefPubMed

30.

Yaffe MJ, Mainprize JG (2011) Risk of radiation-induced breast cancer from mammographic screening. Radiology 258(1):98–105. doi:10.1148/radiol.10100655 CrossRefPubMed

31.

Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, Kerlikowske K, Fenton JJ, Melnikow J, de Koning HJ, Hubbard RA (2016) Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med 164(4):205–214. doi:10.7326/M15-1241 CrossRefPubMedPubMedCentral

32.

Gotzsche PC, Nielsen M (2011) Screening for breast cancer with mammography. Cochrane Database Syst Rev 1:CD001877. doi:10.1002/14651858.CD001877.pub4

33.

Biller-Andorno N, Juni P (2014) Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 370(21):1965–1967. doi:10.1056/NEJMp1401875 CrossRefPubMed

34.

Chantal Cases MDP, Eric Drahi, Sylvie Fainzang (2016) Concertation citoyenne et scientifique. Rapport du comité d’orientation

35.

Organization WH (2014) Position paper on mammography screening. WHO, Geneva, p 78

36.

Shyyan R, Masood S, Badwe RA, Errico KM, Liberman L, Ozmen V, Stalsberg H, Vargas H, Vass L, Global Summit D, Pathology P (2006) Breast cancer in limited-resource countries: diagnosis and pathology. Breast J 12(Suppl 1):S27–S37. doi:10.1111/j.1075-122X.2006.00201.x CrossRefPubMed

37.

Health Statistics and Information Systems W (Revision July 2015) Service availability and readiness assessment (SARA): an annual monitoring system for service delivery. Reference Manual

38.

Organisation WH (2007) Cancer control: knowledge into action. WHO Guide for Effective Programmes, Early Detection

39.

Trinidad & Tobago yellow pages http://tntyp.com/. 2016

40.

Office CS Trinidad and Tobago 2011 Population and Housing Census Demographic Report

41.

Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, Schrag D (2010) Geographic access and the use of screening mammography. Med Care 48(4):349–356. doi:10.1097/MLR.0b013e3181ca3ecb CrossRefPubMedPubMedCentral

42.

Autier P, Ouakrim DA (2008) Determinants of the number of mammography units in 31 countries with significant mammography screening. Br J Cancer 99(7):1185–1190. doi:10.1038/sj.bjc.6604657 CrossRefPubMedPubMedCentral

43.

Office USGA mammography: current nationwide capacity is adequate, but access problems may exist in certain locations. U.S. General Accounting Office, Washington, DC

44.

Ranger B, Littrup PJ, Duric N, Chandiwala-Mody P, Li C, Schmidt S, Lupinacci J (2012) Breast ultrasound tomography versus MRI for clinical display of anatomy and tumor rendering: preliminary results. AJR Am J Roentgenol 198(1):233–239. doi:10.2214/AJR.11.6910 CrossRefPubMedPubMedCentral

45.

Malur S, Wurdinger S, Moritz A, Michels W, Schneider A (2001) Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography. Breast Cancer Res 3(1):55–60CrossRefPubMed

46.

Luparia A, Mariscotti G, Durando M, Ciatto S, Bosco D, Campanino PP, Castellano I, Sapino A, Gandini G (2013) Accuracy of tumour size assessment in the preoperative staging of breast cancer: comparison of digital mammography, tomosynthesis, ultrasound and MRI. Radiol Med 118(7):1119–1136. doi:10.1007/s11547-013-0941-z CrossRefPubMed

47.

Shin HJ, Kim HH, Ahn JH, Kim SB, Jung KH, Gong G, Son BH, Ahn SH (2011) Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 84(1003):612–620. doi:10.1259/bjr/74430952 CrossRefPubMedPubMedCentral

48.

Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148(9):671–679CrossRefPubMed

49.

Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O’Loughlin M, Harms S, Bluemke DA, International Breast MRICWG (2005) Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103(9):1898–1905. doi:10.1002/cncr.20971 CrossRefPubMed

50.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518. doi:10.1200/JCO.2009.23.1274 CrossRefPubMed

51.

Early Breast Cancer Trialists’ Collaborative G, Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC (2008) Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 371(9606):29–40. doi:10.1016/S0140-6736(08)60069-0 CrossRef

52.

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0 CrossRef

53.

Early Breast Cancer Trialists’ Collaborative G, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361. doi:10.1016/S0140-6736(15)60908-4 CrossRef

54.

PAH Organisation (2016) Mammography services quality assurance: baseline standards for Latin America and the Caribbean. PAHO, Washington

55.

Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A (2008) Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer 113:2244–2256. doi:10.1002/cncr.23842 CrossRefPubMed

56.

Devi BC, Tang TS, Corbex M (2007) Reducing by half the percentage of late-stage presentation for breast and cervix cancer over 4 years: a pilot study of clinical downstaging in Sarawak, Malaysia. Ann Oncol 18(7):1172–1176. doi:10.1093/annonc/mdm105 CrossRefPubMed

57.

Corbex M, Burton R, Sancho-Garnier H (2012) Breast cancer early detection methods for low and middle income countries, a review of the evidence. Breast 21:428–434. doi:10.1016/j.breast.2012.01.002 CrossRefPubMed

Titel: A situational analysis of breast cancer early detection services in Trinidad and Tobago
verfasst von: Kimberly Badal
Fidel Rampersad
Wayne A. Warner
Adetunji T. Toriola
Hamish Mohammed
Harold-Alexis Scheffel
Rehanna Ali
Murrie Moosoodeen
Siva Konduru
Adaila Russel
Rajini Haraksingh
Publikationsdatum: 11.08.2017
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 1/2018
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-017-0937-4

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A situational analysis of breast cancer early detection services in Trinidad and Tobago

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis

Consumption of caffeinated beverages and serum concentrations of sex steroid hormones in US men

Plasma lipopolysaccharide-binding protein and colorectal cancer risk: a nested case–control study in the Multiethnic Cohort

Meat consumption and pancreatic cancer risk among men and women in the Cancer Prevention Study-II Nutrition Cohort

Factors related to longitudinal adherence in colorectal cancer screening: qualitative research findings

Characterizing the neighborhood obesogenic environment in the Multiethnic Cohort: a multi-level infrastructure for cancer health disparities research

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie